Dr Aaron E. Lisberg reports on key results from ESMO Congress 2023 on LBA12 - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01
Produced by the European Society for Medical Oncology
oncologypro.esmo.org
Негізгі бет Ғылым және технология Highlights on datopotamab deruxtecan in advanced NSCLC: The TROPION-Lung01 study
Пікірлер